MedTrace Logo

Observational Study Evaluating the Quality of Pegylated Interferon Alfa-2a and Ribavirin Treatment for Chronic Hepatitis C in Cooperation With the BNG (Association of German Resident Gastroenterologists)

NCT02106156 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10228

Last updated 2016-09-23

Study results available
· View outcomes & findings →

Summary

This observational study will examine the efficacy and safety of pegylated interferon (peginterferon) alfa-2a, mostly in combination with ribavirin treatment in chronic hepatitis C (CHC). Quality of care will also be assessed. Approximately 12% of the interferon-treated CHC patient population in Germany is expected to be studied over a period of 5 years.

Conditions

  • Chronic Hepatitis C

Interventions

DRUG

Pegylated interferon alfa-2a

Pegylated interferon alfa-2a administered according to corresponding summary of product characteristics (SmPC).

DRUG

Ribavirin

Ribavirin administered according to corresponding summary of product characteristics (SmPC).

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2013-09-30
Completion
2013-09-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02106156 on ClinicalTrials.gov